Autonomous BCR signaling and the CARD11 L251P mutation as alternative oncogenic drivers induce identical gene expression profiles in genetically engineered ABC-DLBCL models
Analysis reveals differential gene expression in ABC-DLBCL models driven by CARD11 L251P mutation and BCR signaling, indicating immune response implications.
Key Points
Differential gene expression revealed significant changes in ABC-DLBCL models using gene editing techniques, highlighting the role of oncogenic drivers.
Three independent RNA sequencing analyses indicated alterations in gene expression profiles linked to immune response mechanisms.
Gene editing of TMD8 and OCI-Ly3 cell lines showcased the functional equivalency between autonomous BCR signaling and CARD11 L251P mutation.
Findings suggest that traditional classifications of DLBCL may overlook the complexity of immunological drivers in cancer.